Subcutaneous · GLP-1 / GIP / glucagon triple
SAR441255
1 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
1
Ongoing
0
Recruiting
0
Completed
1
Sites
1
Countries
1
Endpoints
7
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
1
Trials by status
Completed
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
4
Glycemic / diabetes
3
Top 20 metrics across this asset's endpoints
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
1 of 1
| Asset / Population | Eligibility highlight | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT04521738First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects | SAR441255 Healthy volunteers, Obesity / overweight | BMI 20-30 | Ph 1 | Completed | 1 | Sep 2019 | 1 |
Showing 1-1 of 1 trials